Why We Chose It

Project Healthspan selected the Celluma Pro Flex because it passed every criterion we set: FDA clearance, wavelength precision, flexible form factor, and the kind of clinical backing that holds up under scrutiny. Most panel devices on the market meet one or two of these bars. The Celluma meets all of them.

Beyond its primary indications, the Celluma also shows promise for mood support and anxiety reduction when used on the face — based on secondary literature and our own experience with the device.^{[1b.05][1b.13][1f.01]} Note that those citations come from transcranial PBM research — the most directly relevant literature available — rather than panel-specific studies. Our Try Light program gives members the time they need to evaluate results for themselves.

The Bigger Picture

Chronic inflammation is increasingly understood as a driver not just of pain and physical decline, but of cognitive aging and neurodegenerative disease. It does its damage slowly and systemically — and it responds to intervention at the cellular level.

Photobiomodulation works by stimulating cytochrome c oxidase in the mitochondria — the primary energy-producing structures in our cells — triggering a cascade that increases ATP production, reduces oxidative stress, and modulates inflammatory signaling throughout the body.^[1b.16] These are not cosmetic effects. For members focused on long-term healthspan and cognitive preservation, whole-body red and near-infrared therapy is a meaningful part of a broader protocol.

Safety Profile

FDA clearance means the agency has reviewed the device and passed it for safety — a bar most competing panels have not cleared. The Celluma Pro holds clearance across multiple indications, each requiring documented safety data.

Unlike pharmaceutical interventions for pain or inflammation — which commonly carry GI, cardiovascular, or hepatic risks — photobiomodulation produces its effects at the cellular level, without systemic drug exposure.^[1b.16] The light is non-ionizing, non-thermal at therapeutic doses, and leaves no recovery period. Across published clinical trials, no serious adverse effects have been reported at standard use parameters. For members managing chronic pain or inflammation alongside a broader healthspan protocol, this profile matters.